Literature DB >> 12782787

Expression profiles of acute lymphoblastic and myeloblastic leukemias with ALL-1 rearrangements.

T Rozovskaia1, O Ravid-Amir, S Tillib, G Getz, E Feinstein, H Agrawal, A Nagler, E F Rappaport, I Issaeva, Y Matsuo, U R Kees, T Lapidot, F Lo Coco, R Foa, A Mazo, T Nakamura, C M Croce, G Cimino, E Domany, E Canaani.   

Abstract

The ALL-1 gene is directly involved in 5-10% of acute lymphoblastic leukemias (ALLs) and acute myeloid leukemias (AMLs) by fusion to other genes or through internal rearrangements. DNA microarrays were used to determine expression profiles of ALLs and AMLs with ALL-1 rearrangements. These profiles distinguish those tumors from other ALLs and AMLs. The expression patterns of ALL-1-associated tumors, in particular ALLs, involve oncogenes, tumor suppressors, antiapoptotic genes, drug-resistance genes, etc., and correlate with the aggressive nature of the tumors. The genes whose expression differentiates between ALLs with and without ALL-1 rearrangement were further divided into several groups, enabling separation of ALL-1-associated ALLs into two subclasses. One of the groups included 43 genes that exhibited expression profiles closely linked to ALLs with ALL-1 rearrangements. Further, there were evident differences between the expression profiles of AMLs in which ALL-1 had undergone fusion to other genes and AMLs with partial duplication of ALL-1. The extensive analysis described here pinpointed genes that might have a direct role in pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782787      PMCID: PMC164677          DOI: 10.1073/pnas.1132115100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

Review 1.  Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?

Authors:  Gabriel A Rabinovich; Linda G Baum; Nicola Tinari; Roberto Paganelli; Clara Natoli; Fu Tong Liu; Stefano Iacobelli
Journal:  Trends Immunol       Date:  2002-06       Impact factor: 16.687

2.  B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines.

Authors:  M Arsura; M Introna; F Passerini; A Mantovani; J Golay
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

3.  DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation.

Authors:  T Raveh; G Droguett; M S Horwitz; R A DePinho; A Kimchi
Journal:  Nat Cell Biol       Date:  2001-01       Impact factor: 28.824

Review 4.  MYC oncogenes and human neoplastic disease.

Authors:  C E Nesbit; J M Tersak; E V Prochownik
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

5.  Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation.

Authors:  A Paz; R Haklai; G Elad-Sfadia; E Ballan; Y Kloog
Journal:  Oncogene       Date:  2001-11-08       Impact factor: 9.867

6.  A stem cell molecular signature.

Authors:  Natalia B Ivanova; John T Dimos; Christoph Schaniel; Jason A Hackney; Kateri A Moore; Ihor R Lemischka
Journal:  Science       Date:  2002-09-12       Impact factor: 47.728

7.  Roles of Mcm7 and Mcm4 subunits in the DNA helicase activity of the mouse Mcm4/6/7 complex.

Authors:  Zhiying You; Yukio Ishimi; Hisao Masai; Fumio Hanaoka
Journal:  J Biol Chem       Date:  2002-08-30       Impact factor: 5.157

8.  Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias.

Authors:  D C Tkachuk; S Kohler; M L Cleary
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

9.  A p34(cdc2) survival checkpoint in cancer.

Authors:  Daniel S O'Connor; Nathan R Wall; Andrew C G Porter; Dario C Altieri
Journal:  Cancer Cell       Date:  2002-07       Impact factor: 31.743

Review 10.  Insulin-like growth factors and cancer.

Authors:  Gregor Fürstenberger; Hans-Jörg Senn
Journal:  Lancet Oncol       Date:  2002-05       Impact factor: 41.316

View more
  21 in total

1.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation.

Authors:  Kira Orlovsky; Alexander Kalinkovich; Tanya Rozovskaia; Elias Shezen; Tomer Itkin; Hansjuerg Alder; Hatice Gulcin Ozer; Letizia Carramusa; Abraham Avigdor; Stefano Volinia; Arthur Buchberg; Alex Mazo; Orit Kollet; Corey Largman; Carlo M Croce; Tatsuya Nakamura; Tsvee Lapidot; Eli Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

3.  Reproducibility, fidelity, and discriminant validity of mRNA amplification for microarray analysis from primary hematopoietic cells.

Authors:  Liang Li; Joe Roden; Bruce E Shapiro; Barbara J Wold; Smita Bhatia; Stephen J Forman; Ravi Bhatia
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

4.  Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia.

Authors:  Matthew G Guenther; Lee N Lawton; Tatiana Rozovskaia; Garrett M Frampton; Stuart S Levine; Thomas L Volkert; Carlo M Croce; Tatsuya Nakamura; Eli Canaani; Richard A Young
Journal:  Genes Dev       Date:  2008-12-15       Impact factor: 11.361

5.  Gene expression profiles in acute myeloid leukemia with common translocations using SAGE.

Authors:  Sanggyu Lee; Jianjun Chen; Guolin Zhou; Run Zhang Shi; Gerard G Bouffard; Masha Kocherginsky; Xijin Ge; Miao Sun; Nimanthi Jayathilaka; Yeong Cheol Kim; Neelmini Emmanuel; Stefan K Bohlander; Mark Minden; Justin Kline; Ozden Ozer; Richard A Larson; Michelle M LeBeau; Eric D Green; Jeffery Trent; Theodore Karrison; Piu Paul Liu; San Ming Wang; Janet D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

6.  The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.

Authors:  Susan P Whitman; Shujun Liu; Tamara Vukosavljevic; Laura J Rush; Li Yu; Chunhui Liu; Marko I Klisovic; Kati Maharry; Martin Guimond; Matthew P Strout; Brian Becknell; Adrienne Dorrance; Rebecca B Klisovic; Christoph Plass; Clara D Bloomfield; Guido Marcucci; Michael A Caligiuri
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

Review 7.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

8.  Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in pediatric acute lymphoblastic leukemia.

Authors:  Alex H Beesley; Janelle L Rampellini; Misty-Lee Palmer; Jasmin Y S Heng; Amy L Samuels; Martin J Firth; Jette Ford; Ursula R Kees
Journal:  Mol Cancer       Date:  2010-10-28       Impact factor: 27.401

9.  HOX proteins and leukemia.

Authors:  Kajal V Sitwala; Monisha N Dandekar; Jay L Hess
Journal:  Int J Clin Exp Pathol       Date:  2008-03-30

10.  ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias.

Authors:  Hiroshi Nakanishi; Tatsuya Nakamura; Eli Canaani; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.